The IMMERGE registry is an observational, international multicentric study, including patients underwent IMPELLA implantation in the participating centers both for cardiogenic shock and high-risk PCI. Only IMPELLA CP, 5.0 and 5.5 devices will be included. Consecutive patients with CS and CHIPs implanted with Impella® CP, 5.0 and 5.5 with at least 6 months of follow-up completed will be enrolled in the registry. Baseline clinical and echocardiographic variables, peri-procedural haemodynamic parameters, laboratoristic findings and complications, together with follow-up outcomes data will be recorded in a dedicated database.
Study Type
OBSERVATIONAL
Enrollment
700
To implante Impella
AOU Città della Salute e della Scienza di Torino
Torino, Italy, Italy
long-term overall mortality
Time frame: 12 months
30-day overall and cardiovascular mortality
Time frame: 30 day
Rate of acute kidney injury (AKIN classification) and need for renal replacement therapy (RRT)
Time frame: 12 months
Rate of bleedings according to the BARC classification
Time frame: 12 months
Rate of vascular complications, limb-ischemia, hemolysis (INTERMACS definition)
Time frame: 12 months
Rate of neurological events (stroke and TIA)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.